Analysts Offer Predictions for VVOS Q1 Earnings

Vivos Therapeutics, Inc. (NASDAQ:VVOS) – Research analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Vivos Therapeutics in a research note issued on Friday, April 17th. HC Wainwright analyst Y. Chen anticipates that the company will post earnings per share of ($0.49) for the quarter. HC Wainwright currently has a “Buy” rating and a $2.50 target price on the stock. The consensus estimate for Vivos Therapeutics’ current full-year earnings is ($1.71) per share. HC Wainwright also issued estimates for Vivos Therapeutics’ Q2 2026 earnings at ($0.33) EPS, Q3 2026 earnings at ($0.25) EPS, Q4 2026 earnings at ($0.20) EPS and FY2026 earnings at ($1.18) EPS.

Vivos Therapeutics (NASDAQ:VVOS) last posted its quarterly earnings results on Wednesday, April 15th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.08). The business had revenue of $3.82 million during the quarter, compared to the consensus estimate of $7.10 million. Vivos Therapeutics had a negative return on equity of 849.22% and a negative net margin of 121.37%.During the same quarter in the previous year, the business posted ($2.22) earnings per share.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Vivos Therapeutics in a research report on Monday. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $3.42.

Vivos Therapeutics Trading Up 2.0%

Shares of NASDAQ:VVOS opened at $1.03 on Wednesday. The company has a market cap of $13.89 million, a PE ratio of -0.50 and a beta of 6.93. The company’s 50-day moving average price is $1.33 and its 200 day moving average price is $1.93. Vivos Therapeutics has a fifty-two week low of $0.96 and a fifty-two week high of $7.95. The company has a quick ratio of 0.24, a current ratio of 0.24 and a debt-to-equity ratio of 3.31.

Institutional Investors Weigh In On Vivos Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Acorn Wealth Advisors LLC acquired a new stake in Vivos Therapeutics in the fourth quarter worth approximately $30,000. XTX Topco Ltd acquired a new stake in Vivos Therapeutics in the second quarter worth approximately $65,000. B. Riley Wealth Advisors Inc. acquired a new stake in Vivos Therapeutics in the second quarter worth approximately $220,000. DRW Securities LLC lifted its position in Vivos Therapeutics by 179.5% in the fourth quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock worth $235,000 after purchasing an additional 74,441 shares during the period. Finally, Connective Capital Management LLC acquired a new stake in Vivos Therapeutics in the third quarter worth approximately $620,000. 26.35% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Vivos Therapeutics

In other news, major shareholder Michael C. Skaff bought 1,353,625 shares of the business’s stock in a transaction on Tuesday, March 31st. The stock was purchased at an average cost of $1.34 per share, for a total transaction of $1,813,857.50. Following the completion of the transaction, the insider directly owned 1,353,625 shares of the company’s stock, valued at approximately $1,813,857.50. This trade represents a ? increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.10% of the stock is owned by corporate insiders.

About Vivos Therapeutics

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.